Chongqing Lummy Pharmaceutical Co., Ltd. reported earnings results for the nine months ended September 30, 2023. For the nine months, the company reported sales was CNY 644.76 million compared to CNY 670.85 million a year ago. Revenue was CNY 644.76 million compared to CNY 670.85 million a year ago.

Net loss was CNY 54.51 million compared to CNY 37.37 million a year ago. Basic loss per share from continuing operations was CNY 0.0516 compared to CNY 0.0354 a year ago. Diluted loss per share from continuing operations was CNY 0.0516 compared to CNY 0.0354 a year ago.